Erste Asset Management

What potential do biotechnology shares hold?

What potential do biotechnology shares hold?
What potential do biotechnology shares hold?
Share post:

Why is everybody talking about biotechnology (“biotech”) shares?

The shares of companies of the biotechnology sector are definitely among the ones with the highest growth opportunities, but also the ones subject to the most drastic price fluctuations. Investment funds offer a diversified approach, i.e. they invest in a larger number of interesting, listed biotech companies. One of those funds is ESPA STOCK BIOTEC . After a setback in 2015, it has been on the upswing ever since (see the chart below; source: Thomson Reuters Datastream, 22 February 2019*). Chances are that biotech shares will maintain their growth momentum in the coming years. The biotech sector has seen a renewed spirit of optimism lately. Pioneering research results in diseases with high needs of medical input and persistent sales and earnings growth are plausible buying arguments.

*) Historical performance data are not indicative of the future development of the fund.

Biotechnology in a nutshell

Biotechnology is a technology that is based on biology. It makes use of cellular and biomolecular processes in developing new medicines. At the moment, patients have more than 250 biotechnological products and vaccines at their disposal, many of them for previously untreatable diseases. Biotechnology is a collective term for a vast number of procedures, products, and methods. The application of biotechnology is not limited to one field but is versatile. For example, biotechnologists research small and large organisms, plants, animals, and humans as well as minuscule parts such as cells and molecules. (source: OECD)

Areas of biotechnology

Green Biotechnology encompasses herbal, plant-based applications e.g. for agricultural purposes. Red Biotechnology is the area of medical/pharmaceutical applications such as e.g. the production of medication and diagnostic items. White Biotechnology – or industrial biotechnology – comprises biotechnological production methods especially for chemical compounds in the chemical industry as well as processes in the textile and food industry. (source: BMBF, Deutschland)

Healthcare expenditures are globally on the rise

The healthcare industry is regarded as leading industry of the 21st century. Due to global population growth to 9.2bn by 2050 and the predicted doubling of the population of people above the age of 60 by then, healthcare expenditures in the OECD countries will increase from currently 6 percent of GDP to 9.5 percent. (source: OECD)

The biotechnology sector will benefit from the development of new, innovative, and successful medications. For the coming years, sales and earnings are expected to grow in the high single digits.The FDA approved a record number of 59 new medications in 2018 (after 40 in 2017) in the USA (source: FDA). The USA is an R&D leader and will continue to support innovation.

What are the growth drivers in biotechnology?

  • The mapping of the human brain has revolutionised the development of medications. Despite many innovations and successes in research, only a few medications are on the market for the 1,200 so-called rare diseases. This is where biotechnology can hopefully make a contribution.
  • The fight against cancer. According to the WHO, 9.6mn people died from cancer last year. The costs of this treacherous disease amount to a gigantic USD 1,200bn annually. Many diseases have not been fully researched yet, so there is no effective medication either. This may soon change. New medications can be used against various forms of cancer, for example Revlimid von Celgene, which treats multiple myeloma. The clinical trials by Bristol-Myers for Opdivo were less successful. At the end of last year, the company had to announce that the treatment of patients with lung carcinoma had been a failure.
  • Lifestyle diseases like diabetes (422mn adult sufferers worldwide) or liver diseases have to be fought effectively. The Danish company Novo Nordisk is currently testing a substance against fatty liver, which can at the same time be used against Alzheimer’s
  • Immune therapies represent the new age of cancer therapy. At the moment, cellular approaches seem promising.
  • In addition, the pipelines are well-stocked in the field of neurological diseases. The latest breakthroughs have come from medications against severe forms of epilepsy and postpartum depression.
  • Increased number of company acquisitions and takeovers. Expiring patents in the pharmaceutical and biotech sector put the former success story at risk and have to be offset by new products. Company acquisitions and takeovers are a way of maintaining growth. At the end of February, the US diagnostics and biotechnology group Danaher announced the takeover of the pharmaceutical business unit of General Electric for USD 21.4bn. Meanwhile, the Swiss pharmaceutical group Roche agreed to take over the US biotech company Spark for USD 4.3bn and thus for the first time engages with gene therapy (source: Handelsblatt, 26 February 2019). Further examples are the takeovers of Celgene by Bristol Myers, Loxo by Eli Lilly, Tesaro by GlaxoSmithKline, and IMDZ by Merck.

Setback risks for biotechnology

The trade-off for the basically positive growth perspectives of the biotechnology industry is the risk of potential setbacks that should not be underestimated. In the most recent US presidential election campaign, the influence of politics on the pricing of medication came with a negative effect. Both Hillary Clinton and Donald Trump declared themselves in favour of lower drug prices. But if innovations are not being paid for and prices are also strongly regulated, will there be any innovation?

Another factor that could be detrimental to growth in the future is the concentration of research and entrepreneurialism in US biotech companies. The biotech cluster is based in the USA and not in Europe. This does not mean that Europe does not generate innovation, but the degree does not measure up to the USA. In the USA, there are some clusters around Boston, San Francisco, and New York, where companies have set up joint research projects. This approach does not exist to the same extent in Europe. The few that do exist in the UK, France, Germany, and Sweden are not comparable to what is going on in the USA in terms of size. Also, the Anglo-Saxon attitude towards risk is different than the European one. Venture capital that is needed to be successful more quickly is more readily available in the USA than in Europe. 

ESPA STOCK BIOTEC: portfolio invested in top biotech companies

Investors looking for an investment vehicle that diversifies across the global biotechnology sector can for example invest in ESPA STOCK BIOTEC. The fund was issued in 2000 by Erste Asset Management and invests in a portfolio that consists of about 80 listed companies, mainly from the USA, which is regarded as global biotech centre. Since its launch date, ESPA STOCK BIOTEC has achieved an annual performance of 8.70% (as of 31 January 2019; source:*. This fund captures all essential areas of application of biotechnology such as for example cancer research, personalised medicine, Alzheimer’s, cell therapy, rare diseases, and gene therapy. By investing in ESPA STOCK BIOTEC, investors may benefit from rising share prices but at the same time have to be willing to take risks and possibly accept significant price fluctuations. The timing risk can be contained by setting up a fund savings plan with regular investments (s Fonds Plan / s fund plan).

Note: Depending on the performance of the investment fund, the performance of an s Fonds Plan will differ from that of a single investment (higher or lower). A loss of capital is possible in both cases.

*Performance calculated according to the OeKB method. The performance accounts for the management fee and any performance fee. It does not allow for a one-time load of up to 4.00%, if applicable at the time of purchase, nor any other fees reducing return such as individual account or depositary fees. Historical performance data are not indicative of the future development of the fund.

For legal documents and additional information on the aforementioned fund, please visit

ESPA STOCK BIOTEC – (ISIN AT0000746755 T, ISIN AT0000746748 A)

 Benefits for the investor:

  • Participation in the world’s most important biotechnology companies
  • Chance of significant increase in prices
  • Optimum diversification across global biotechnology companies even with small investment
  • Suitable for fund savings plan (s Fonds Plan)

Risks to be aware of:

  • The fund price may fluctuate significantly (i.e. high volatility)
  • The investor bears the sector risk of the US biotechnology sector
  • Due to the investment in foreign currency, the value of the fund and its shares may be affected by fluctuations in foreign exchange rates
  • Capital loss is possible


Shares from the biotechnology sector are drawing attention from investors, and rightly so. For the coming years, sales and earnings are expected to grow in high single digits.” Like in previous years, new research results and mergers could support share prices. Investors should bear the risks in mind when investing. The share prices in the biotech sector are likely to be subject to high volatility also in the future.

Legal note:
Prognoses are no reliable indicator for future performance.


Legal disclaimer

This document is an advertisement. Unless indicated otherwise, source: Erste Asset Management GmbH. The language of communication of the sales offices is German and the languages of communication of the Management Company also include English.

The prospectus for UCITS funds (including any amendments) is prepared and published in accordance with the provisions of the InvFG 2011 as amended. Information for Investors pursuant to § 21 AIFMG is prepared for the alternative investment funds (AIF) administered by Erste Asset Management GmbH pursuant to the provisions of the AIFMG in conjunction with the InvFG 2011.

The currently valid versions of the prospectus, the Information for Investors pursuant to § 21 AIFMG, and the key information document can be found on the website under “Mandatory publications” and can be obtained free of charge by interested investors at the offices of the Management Company and at the offices of the depositary bank. The exact date of the most recent publication of the prospectus, the languages in which the key information document is available, and any other locations where the documents can be obtained are indicated on the website A summary of the investor rights is available in German and English on the website and can also be obtained from the Management Company.

The Management Company can decide to suspend the provisions it has taken for the sale of unit certificates in other countries in accordance with the regulatory requirements.

Note: You are about to purchase a product that may be difficult to understand. We recommend that you read the indicated fund documents before making an investment decision. In addition to the locations listed above, you can obtain these documents free of charge at the offices of the referring Sparkassen bank and the offices of Erste Bank der oesterreichischen Sparkassen AG. You can also access these documents electronically at

N.B.: The performance scenarios listed in the key information document are based on a calculation method that is specified in an EU regulation. The future market development cannot be accurately predicted. The depicted performance scenarios merely present potential earnings, but are based on the earnings in the recent past. The actual earnings may be lower than indicated. Our analyses and conclusions are general in nature and do not take into account the individual characteristics of our investors in terms of earnings, taxation, experience and knowledge, investment objective, financial position, capacity for loss, and risk tolerance.

Please note: Past performance is not a reliable indicator of the future performance of a fund. Investments in securities entail risks in addition to the opportunities presented here. The value of units and their earnings can rise and fall. Changes in exchange rates can also have a positive or negative effect on the value of an investment. For this reason, you may receive less than your originally invested amount when you redeem your units. Persons who are interested in purchasing units in investment funds are advised to read the current fund prospectus(es) and the Information for Investors pursuant to § 21 AIFMG, especially the risk notices they contain, before making an investment decision. If the fund currency is different than the investor’s home currency, changes in the relevant exchange rate can positively or negatively influence the value of the investment and the amount of the costs associated with the fund in the home currency.

We are not permitted to directly or indirectly offer, sell, transfer, or deliver this financial product to natural or legal persons whose place of residence or domicile is located in a country where this is legally prohibited. In this case, we may not provide any product information, either.

Please consult the corresponding information in the fund prospectus and the Information for Investors pursuant to § 21 AIFMG for restrictions on the sale of the fund to American or Russian citizens.

It is expressly noted that this communication does not provide any investment recommendations, but only expresses our current market assessment. Thus, this communication is not a substitute for investment advice, does not take into account the legal regulations aimed at promoting the independence of financial analyses, and is not subject to a prohibition on trading following the distribution of financial analyses.

This document does not represent a sales activity of the Management Company and therefore may not be construed as an offer for the purchase or sale of financial or investment instruments.

Erste Asset Management GmbH is affiliated with the referring Sparkassen banks and Erste Bank.

Please also read the “Information about us and our securities services” published by your bank.

Subject to misprints and errors.